Nuvectis Pharma, Inc. (NVCT)
24.63
+0.76
(+3.18%)
USD |
NASDAQ |
Aug 25, 13:02
Nuvectis Pharma Enterprise Value : 615.04M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 615.04M |
| August 21, 2026 | 606.77M |
| August 20, 2026 | 601.16M |
| August 19, 2026 | 600.63M |
| August 18, 2026 | 536.03M |
| August 17, 2026 | 487.18M |
| August 14, 2026 | 483.97M |
| August 13, 2026 | 491.18M |
| August 12, 2026 | 499.46M |
| August 11, 2026 | 495.99M |
| August 10, 2026 | 481.70M |
| August 07, 2026 | 483.71M |
| August 06, 2026 | 480.50M |
| August 05, 2026 | 491.98M |
| August 04, 2026 | 514.41M |
| August 03, 2026 | 554.45M |
| July 31, 2026 | 552.31M |
| July 30, 2026 | 585.41M |
| July 29, 2026 | 530.16M |
| July 28, 2026 | 506.93M |
| July 27, 2026 | 499.46M |
| July 24, 2026 | 493.32M |
| July 23, 2026 | 515.74M |
| July 22, 2026 | 492.78M |
| July 21, 2026 | 487.18M |
| Date | Value |
|---|---|
| July 20, 2026 | 459.15M |
| July 17, 2026 | 488.78M |
| July 16, 2026 | 474.36M |
| July 15, 2026 | 500.79M |
| July 14, 2026 | 466.09M |
| July 13, 2026 | 470.09M |
| July 10, 2026 | 467.69M |
| July 09, 2026 | 484.77M |
| July 08, 2026 | 478.37M |
| July 07, 2026 | 490.38M |
| July 06, 2026 | 501.86M |
| July 02, 2026 | 500.26M |
| July 01, 2026 | 498.92M |
| June 30, 2026 | 468.76M |
| June 29, 2026 | 731.64M |
| June 26, 2026 | 696.10M |
| June 25, 2026 | 714.14M |
| June 24, 2026 | 624.21M |
| June 23, 2026 | 440.39M |
| June 22, 2026 | 413.34M |
| June 18, 2026 | 341.45M |
| June 17, 2026 | 308.83M |
| June 16, 2026 | 291.58M |
| June 15, 2026 | 270.63M |
| June 12, 2026 | 258.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Decoy Therapeutics, Inc. | -6.635M |
| Unicycive Therapeutics, Inc. | 88.06M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.02M |
| Total Expenses (Quarterly) | 7.02M |
| EPS Diluted (Quarterly) | -0.299 |
| Earnings Yield | -5.19% |
| Normalized Earnings Yield | -5.187 |